"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...
Please provide your email address to receive an email when new articles are posted on . Low body surface area psoriasis in sensitive or highly visible areas is often prescribed only topical ...
On Friday, Johnson & Johnson (NYSE:JNJ) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate ...
First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & ...
Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...
The recommended dosage for active PsA and moderate to severe plaque PsO in pediatric patients 6 years (≥40kg) is 100mg administered SC at week 0, 4, and then every 8 weeks thereafter. The Food and ...
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results